Clinical Trials
4 trialsNCT06764160 2026-01-15
ECU-MG-304
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT03759366 2024-12-11
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT02301624 2020-02-05
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT01997229 2019-07-16
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
Alexion Pharmaceuticals, Inc.
Phase 3 Completed